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KEY POINTS 39 
1. Genetic perturbation of the ubiquitin proteasome system is an emerging hallmark of B-40 
cell non-Hodgkin lymphoma (B-NHL). 41 
2. Co-occurring sets of genetic alterations define B-NHL subtypes and likely represent 42 
epistatic interactions.  43 
 44 
ABSTRACT 45 
B-cell non-Hodgkin lymphoma (B-NHL) encompasses multiple clinically and phenotypically 46 
distinct subtypes of malignancy with unique molecular etiologies. Common subtypes of B-NHL 47 
such as diffuse large B-cell lymphoma (DLBCL) have been comprehensively interrogated at the 48 
genomic level, but other less common subtypes such as mantle cell lymphoma (MCL) remain 49 
sparsely characterized. Furthermore, multiple B-NHL subtypes have thus far not been 50 
comprehensively compared to identify conserved or subtype-specific patterns of genomic 51 
alterations. Here, we employed a large targeted hybrid-capture sequencing approach 52 
encompassing 380 genes to interrogate the genomic landscapes of 755 B-NHL tumors at high 53 
depth; primarily including DLBCL, MCL, follicular lymphoma (FL), and Burkitt lymphoma (BL). 54 
We identified conserved hallmarks of B-NHL that were deregulated across major subtypes, such 55 
as the frequent genetic deregulation of the ubiquitin proteasome system (UPS). In addition, we 56 
identified subtype-specific patterns of genetic alterations, including clusters of co-occurring 57 
mutations that are pathognomonic. The cumulative burden of mutations within a single cluster 58 
were more significantly discriminatory of B-NHL subtypes than individual mutations, implicating 59 
likely patterns of genetic epistasis that contribute to disease etiology. We therefore provide a 60 
framework of co-occurring mutations that deregulate genetic hallmarks and likely cooperate in 61 
lymphomagenesis of B-NHL subtypes. 62 
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INTRODUCTION 63 
Non-Hodgkin lymphomas (NHL) are a heterogeneous group of lymphoid malignancies that 64 
predominantly arise from mature B-cells (B-NHL). Although mature B-cell neoplasms 65 
encompass 38 unique diagnostic subtypes, over 85% of cases fall within only 7 subtypes1,2. 66 
Recent next generation sequencing (NGS) studies have shed light onto the key driver mutations 67 
in many of these NHL subtypes; for example, large studies of diffuse large B-cell lymphoma 68 
(DLBCL) have led to proposed genomic subtypes that have unique etiologies3-5. However, many 69 
less-common NHL subtypes such as mantle cell lymphoma (MCL) have not been as extensively 70 
characterized6,7. Furthermore, until recently3,4 genetic alterations have been considered in a 71 
binary fashion as either driver events, which directly promote disease genesis or progression, or 72 
passenger events, which have little or no impact on disease biology. In contrast to this principle, 73 
most B-NHLs do not result from a single dominant driver but instead result from the serial 74 
acquisition of genetic alterations that cooperate in lymphomagenesis. The genetic context of 75 
each mutation therefore likely determines its oncogenic potential, and groups of mutations 76 
should therefore be considered collectively rather than as singular events. For example, the ‘C5’ 77 
and ‘MCD’ clusters identified in DLBCL by Chapuy et al. and Schmitz et al., respectively, are 78 
characterized by the co-occurrence of CD79B and MYD88 mutations3,4. In animal models, the 79 
Myd88 L265P mutation was found to promote down-regulation of surface IgM and a phenotype 80 
resembling B-cell anergy8. However, this effect could be rescued by Cd79b mutation, showing 81 
that these co-occurring mutations are epistatic8. The characterization of other significantly co-82 
occurring genetic alterations are therefore likely to reveal additional important epistatic 83 
relationships. 84 
 85 
We approached this challenge by performing genomic profiling of 755 B-NHLs across different 86 
subtypes. Through this cross-sectional analysis we characterized genomic hallmarks of B-NHL 87 
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and identified pathognomonic genetic alterations, including disease-specific mechanisms for 88 
deregulating hallmark processes and protein complexes, and sets of significantly co-associated 89 
events that represent subtype-specific epistatic genetic alterations. This study therefore 90 
provides new insight into how cooperating genetic alterations may contribute to molecularly and 91 
phenotypically distinct subtypes of B-NHL. 92 
 93 
METHODS 94 
An overview of our approach is shown in Figure S1. For detailed methods, please refer to 95 
supplementary information. 96 
 97 
Tumor DNA samples 98 
We collected DNA for 755 B-NHL tumors, including 199 follicular lymphoma (FL), 196 mantle 99 
cell lymphoma (MCL), 148 diffuse large B-cell lymphoma (DLBCL), 108 Burkitt’s lymphoma 100 
(BL), 45 chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL), 24 marginal 101 
zone lymphoma (MZL), 21 high-grade B-cell lymphoma not otherwise specified (HGBL-NOS), 102 
and 14 high-grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangement (DHL) (Table 103 
S1). A total of 502 samples were obtained from the University of Nebraska Medical Center, and 104 
were prioritized for inclusion in this study if they had fresh/frozen tissue available (n=577) and 105 
been previously interrogated by Affymetrix U133 Plus 2.0 gene expression microarrays 106 
(n=290)9-11. An additional series of 178 formalin-fixed paraffin-embedded (FFPE) tumors were 107 
collected from other centers. Samples were de-identified but accompanied by their diagnosis 108 
from medical records, plus overall survival time and status (alive, dead) when available. Medical 109 
record diagnosis was used in all cases except for those with fluorescence in situ hybridization 110 
showing translocations in MYC and BCL2 and/or BCL6, which were amended to DHL. 111 
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Sequencing results for a subset of 52 BL tumors was described previously12. All MCL samples 112 
were either positive for CCND1 translocation by FISH or positive for CCND1 protein expression 113 
by IHC, depending on the diagnostic practices of the contributing institution. 114 
 115 
Next generation sequencing 116 
A total of 100-1000ng of gDNA was sonicated using a Covaris S2 Ultrasonicator, and libraries 117 
prepared using KAPA Hyper Prep Kits (Roche) with TruSeq Adapters (Bioo Scientific) and a 118 
maximum of 8 cycles of PCR (average of 6 cycles). Libraries were qualified by TapeStation 119 
4200, quantified by Qubit and 10- to 12-plexed for hybrid capture. Each multiplexed library was 120 
enriched using our custom LymphoSeq panel encompassing the full coding sequences of 380 121 
genes that have previously been reported to be somatically mutated in B-cell lymphoma6,7,13-32 122 
(Table S2, Supplementary Methods), as well as tiling recurrent translocation breakpoints. 123 
Enrichments were amplified with 4-8 cycles of PCR and sequenced on a single lane of an 124 
Illumina HiSeq 4000 with 100PE reads in high-output mode at the Hudson Alpha Institute for 125 
Biotechnology or the MD Anderson Sequencing and Microarray Facility. Variants were called 126 
using our previously validated ensemble approach12,21, copy number alterations identified using 127 
off-target reads with the CopyWriteR tool33, and translocation called using FACTERA34. 128 
Germline polymorphisms were filtered using dbSNP annotation and the EXAC dataset 129 
containing 60,706 healthy individuals35. Significantly mutated genes were defined by 130 
MutSig2CV36, significant DNA copy number alterations by GISTIC237, and the clonal 131 
representation of mutations by ABSOLUTE38. Mutation and CNA data are publicly viewable 132 
through cBioPortal: https://www.cbioportal.org/study/summary?id=mbn_mdacc_2013. For 133 
further details, refer to supplementary methods. 134 
 135 
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RESULTS 136 
Recurrently mutated genes highlight conserved functional hallmarks of B-NHL 137 
We used a 380 gene custom targeted sequencing approach to interrogate the genomes of 755 138 
mature B-NHLs, sequencing to an average depth of 599X (Min, 101X; Max, 1785X; Table S1) 139 
for a total yield of 2.06 Tbp. Somatic nucleotide variants (SNVs) and small insertions/deletions 140 
(InDels) were identified using an ensemble approach that we have previously validated21 (Table 141 
S3) and significantly mutated genes were identified using MutSig2CV (Table S4). Genes that 142 
were significantly mutated in the full cohort or in any one of the 4 subtypes with >100 tumors 143 
(BL, DLBCL, FL, MCL), as well as frequently mutated genes that are targets of AID (Table S5, 144 
Figure 1), were included in downstream analyses. Mutation distributions were classified using a 145 
novel metric that classifies them into hotspot, clustered or diffuse (Figure S2). The residue of 146 
mutational hotspots and conserved domains targeted by clustered mutations are shown on 147 
figure 1. As a proof of principle, genes such as EZH2 and MYD88 with known mutational 148 
hotspots were classified as ‘hotspot’, and genes such as CREBBP and TCF3 that accumulate 149 
mutations within a single domain were classified as ‘clustered’. The mutational burden 150 
calculated from our targeted region significantly correlated with that from the whole exome 151 
(Figure S3A) and was significantly higher in DLBCL and other high-grade tumors compared to 152 
FL and MCL (Figure 1; Figure S3B). The mutational signatures were also different between 153 
malignancies, but were predominated by mutations attributable to failure of double-strand break 154 
repair by homologous recombination39 (Signature 3; Table S6). 155 
 156 
To identify key hallmarks that are deregulated by somatic mutations, we grouped genes using 157 
DAVID functional annotation clustering40. BCL6 function is not annotated in gene sets within 158 
public databases, but was an obvious feature of the recurrently mutated genes, so this hallmark 159 
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was assigned according to literature support. The most frequently perturbed processes were 160 
chromatin modification and cell signaling, with most of the genes in these categories having 161 
been well described in prior reports. Chromatin modifying genes were mutated in 68% of BL, 162 
66% of DLBCL, 91% of FL and 45% of MCL, and included those that encode proteins that 163 
catalyze post-translational modifications of histones (KMT2D, CREBBP, EZH2, EP300, 164 
WHSC1, ASHL1L and KMT2A), components of the SWI/SNF chromatin remodeling complex 165 
(ARID1A, SMARCA4, BCL7A), linker histones (HIST1H1E, HIST1H1C, HIST1H1B), and the 166 
TET2 gene. Genes with a role in signaling included those involved in B-cell receptor (CD79B, 167 
ID3, TCF3, RFTN1), toll-like receptor (MYD88), NFĸB (TNFAIP3, CARD11, NFKBIE), Notch 168 
(NOTCH1, NOTCH2), JAK/STAT (SOCS1, STAT6), PI3K/mTOR (FOXO1, ATP6V1B2, 169 
APT6AP1) and G-protein (GNA13, GNAI2) signaling. The CD79A and BCL10 genes were also 170 
mutated at a lower frequency that was not significant by MutSig (Figure S4A-B). Among these, 171 
the RFTN1 gene (Figure S4C) is a novel recurrently mutated gene that was mutated in 7.4% of 172 
DLBCL and encodes a lipid raft protein that is critical for B-cell receptor signaling41.  173 
 174 
Other processes that are not as well described as genetic hallmarks of B-NHL included BCL6 175 
function and the ubiquitin proteasome system (UPS). Genes associated with BCL6 function 176 
encompassed BCL6 itself and its interacting proteins (BCL6, TBL1XR1, BCOR, SPEN), 177 
regulators of BCL6 activity or expression (MEF2B, IRF8, IRF4), and a critical BCL6 target gene 178 
(PRDM1). Recurrent mutations of the NCOR1 and NCOR2 genes that encode BCL6 co-179 
repressor proteins were also observed (Figure S4D-E), but were not significant by MutSig2CV. 180 
Multiple recurrently mutated chromatin modifying genes have also been implicated in BCL6 181 
function and therefore also contribute to this hallmark, including CREBBP and EZH242,43. The 182 
recurrently mutated UPS genes included the CDC27 gene, which encodes an E3 ligase for 183 
CCND144 that is mutated in 14% of MCL and has not been previously described in the literature. 184 
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The TMEM51 gene was also identified as a novel recurrently mutated gene in 9% of BL, though 185 
the function of this gene is poorly defined. The cross-sectional analysis of multiple lymphoma 186 
subtypes therefore identified conserved hallmarks that are recurrently targeted by somatic 187 
mutations in B-NHL. 188 
 189 
Enrichment of functional hallmarks by structural alterations 190 
The hybrid capture probes utilized in our design also targeted recurrent breakpoint regions in 191 
the immunoglobulin heavy- and light-chain loci, as well as the regions of recurrent breakpoints 192 
in or near the BCL2, MYC and BCL6 genes. Translocations were called using a method that 193 
detects discordantly mapped reads34 and our prior validation of this approach in cases with 194 
matched fluorescence in situ hybridization (FISH) data for MYC showed that it is 100% specific, 195 
but only ~40% sensitive for translocation detection12. In addition, we failed to detect CCND1 196 
translocations using this approach. However, we did observe a significantly higher fraction of 197 
BCL6 translocations (57% [27/47]) partnered to non-immunoglobulin loci (eg. CIITA, RHOH, 198 
EIF4A2, ST6GAL1; Table S7) compared to BCL2 (1% [1/114]) and MYC (5% [2/38]) 199 
translocations (Figure 2A; Fisher P-value <0.001). These were more frequent in FL (88% 200 
[15/17] of BCL6 translocations) as compared to DLBCL (39% [9/23] of BCL6 translocations), 201 
presumably because the two immunoglobulin loci in FL are either translocated with the BCL2 202 
gene or functioning in immunoglobulin expression45. We also employed off-target reads to 203 
detect DNA copy number alterations (CNAs) in a manner akin to low-pass whole genome 204 
sequencing, identified significant peaks of copy gain and losses using GISTIC237 (Figure 2A; 205 
Figure S5; Table S8-9), and defined the likely targets of these CNAs by integrative analysis of 206 
matched gene expression profiling (GEP) data from 290 tumors (Figure 2B-C, Figure S5, Table 207 
S10-11). This identified known CNA targets (Figure 2D), including but not limited to deletion of 208 
TNFAIP3 (6q24.2)46, ATM (11q22.3)47, B2M (15q15.5)48 and PTEN (10q23.21)49, and copy gain 209 
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of REL and BCL11A (2p15), and TCF4 (18q23)50. In addition, we identified novel targets such 210 
as deletion of IBTK (6q14.1), UBE3A (11q22.1) and FBXO25 (8p23.3), and copy gain of ATF7 211 
(12q13.13), UCHL5 (1q31.3), and KMT2A (11q23.3). Several CNA peaks, defined as the 212 
smallest and most statistically significant region, included genes that were significantly mutated 213 
(Figure 2E) as well as other genes for which we detected mutations at lower frequencies that 214 
were not significant by MutSig (POU2AF1, TP53BP1, FAS, PTEN). Furthermore, for several of 215 
these genes (ATM, B2M, BIRC3 and TNFRSF14), deletions were significantly co-associated 216 
with mutations, suggesting that deletion and mutation are complementary mechanisms 217 
contributing to biallelic inactivation.  218 
 219 
Analyzing targets of translocations and CNAs added to enrichment of functional categories that 220 
we observed within recurrently mutated genes, including chromatin modification (BCL11A) and 221 
signaling (TCF4, PTEN). This was most prominently observed for genes with a role in apoptosis 222 
and the cell cycle (CDKN2A, CDKN2B, FAS, RPL5, DFFB, MDM2, CDK6) and the UPS 223 
(CUL4A, FBXO25, IBTK, RNF38, UBAP1, UBE3A, UBQLN1, UCHL5). Recurrently altered UPS 224 
genes collectively promote or suppress the abundance or activity of proteins with roles in other 225 
hallmark characteristics (Figure 3A). For example; SOCS151, BIRC352, DTX153,54, IBTK55, 226 
TRIM1356, TNFAIP353 and UBE3A53 all inhibit the function of proteins with a role in important B-227 
cell signaling pathways (Figure 3B), thereby establishing a functional link between genetic 228 
alteration of the UPS and deregulation of signaling and adding an additional layer to the 229 
mechanisms by which B-cell receptor signaling is perturbed in B-NHL. The combined analysis of 230 
mutations and structural alterations therefore identified large sets of genes that are targeted by 231 
genetic alterations and collectively contribute to hallmark features that are commonly 232 
deregulated across multiple B-NHL subtypes.  233 
 234 
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 235 
Disease-specific patterns of genetic alterations 236 
Some interesting patterns of disease-specificity were obvious for both mutations and structural 237 
alterations. We therefore formally tested the over- or under-representation of these events in 238 
each of the 4 subtypes with >100 tumors (BL, DLBCL, FL, MCL), compared to all other tumors 239 
in the study (Figure 4; Table S12). Using matched GEP data for a subset of cases (Table S1), 240 
we also tested the association between genetic alterations and molecularly-defined Burkitt’s 241 
lymphoma subtypes (n=154; Figure S6-7, Table S13), as well as DLBCL cell of origin subtypes 242 
(n=98; Figure S7, Table S14). These analyses showed that the genetic alterations associated 243 
with clinically-defined BL were also associated with molecularly-defined BL. Moreover, genetic 244 
alterations that we and others have characterized as being over-represented in ABC-like DLBCL 245 
such as CD79B mutation57, MYD88 mutation58 and TCF4 copy gain50 were significantly over-246 
represented in this analysis also.  247 
 248 
We observed some interesting patterns within hallmark characteristics that differ between 249 
subtypes. For example, linker histone mutations were present in germinal center B (GCB)-cell 250 
derived malignancies (BL, DLBCL, FL) at variable frequencies, but were largely absent from 251 
MCL (Figure S8). In contrast, mutations of genes encoding the H3K36 methyltransferases, 252 
WHSC1 (aka MMSET/NSD2) and ASH1L, were frequent in MCL and largely absent from GCB-253 
derived malignancies. We also noted that the SWI/SNF complex was perturbed in different ways 254 
in different diseases (Figure 5). Specifically, mutations of the SMARCA4 (aka. BRG1) 255 
component of the ATPase module were significantly enriched in BL (24%) compared to other 256 
subtypes (4%, Q-value<0.001), while mutations of the BCL7A component of the ATPase 257 
module were significantly enriched in FL (11%) compared to other subtypes (4%, Q-258 
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value=0.007). In contrast, mutations of ARID1A were frequent in both BL (19%) and FL (15%), 259 
and DNA copy number gains of BCL11A were frequent in both DLBCL (28%) and FL (22%). 260 
The SWI/SNF complex is therefore a target of recurrent genetic alterations, as previously 261 
suggested59, but the manner in which this complex is perturbed varies between B-NHL subtypes 262 
(Figure 5). Similar disease-specific patterns were also observed for signaling genes; for 263 
example, TCF3 and ID3 have important functions in normal germinal center B-cells60, but 264 
mutations of these genes are specifically enriched within BL and are rarely found in the other 265 
GCB-derived malignancies, DLBCL and FL. Similarly, the ATP6AP1 and ATP6V1B2 genes that 266 
function in mTOR signaling61,62 are specifically mutated in FL, and the DUSP2 gene which 267 
inactivates ERK1/263 and STAT364 is specifically mutated in DLBCL. The disease-specific 268 
patterns of genetic alterations therefore reveal subtle but important differences in how each 269 
subtype of B-NHL perturbs hallmark features. 270 
 271 
Pathognomonic sets of co-associated genomic alterations in B-NHL subtypes  272 
We next defined how each genetic alteration co-associated with or mutually-excluded other 273 
genetic alterations by pairwise assessments using false-discovery rate (FDR)-corrected Fisher’s 274 
tests (Table S15). A matrix of the transformed FDR Q-values (-logQ) was used for unsupervised 275 
hierarchical clustering to identify clusters of co-associated genetic alterations. Together with 276 
patterns of disease-specificity, unsupervised clustering revealed clear groupings of co-277 
associated events for BL, DLBCL, FL and MCL (Figure 4). We identified a single cluster that 278 
was specifically enriched in DLBCL, included co-associated genetic alterations that were over-279 
represented in the ABC-like, and overlapped with the previously described C5/MCD clusters3,4. 280 
We also identified a cluster consisting of TP53 mutations and multiple CNAs similar to the C2 281 
subtype reported in DLBCL, but which was enriched in both FL and DLBCL. A cluster with 282 
features similar to the C3/EZB DLBCL clusters was also observed, but was specifically enriched 283 
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in FL. The remaining two previously reported DLBCL clusters (C1/N2 and C4) were not 284 
observed in this analysis, which may be a result of the different clustering strategies used and/or 285 
the lower number of DLBCL tumors in this study compared to other prior DLBCL-focused 286 
efforts3,4. We therefore focused our subsequent description on BL, FL and MCL. 287 
 288 
The core set of co-associated genetic alterations in BL were MYC translocation and mutation, 289 
and mutations of SMARCA4, CCND3 and ID3. Mutations of GNAI2, GNA13, FOXO1, TCF3, 290 
ARID1A and TMEM51 were also clustered with this core set, but were present at lower 291 
frequencies. Mutations of TP53 and copy gain of 1q were frequent in BL, but did not cluster 292 
together with other BL-associated genetic alterations. The core set of genetic alterations in FL 293 
were BCL2 translocations and mutations, and mutations of KMT2D, CREBBP and EZH2, in line 294 
with prior observations16,21. Copy loss of 10q23.31 encompassing the FAS and PTEN genes, 295 
and mutations EEF1A1, TNFRSF14, IRF8, BCL7A, ATP6V1B2 and ATP6AP1 were present at 296 
lower frequencies and clustered with this core set. The MCL cluster included mutations and 297 
deletions of ATM and BIRC3, as well as frequent deletions of 9p21.32 (CDKN2A and CDKN2B), 298 
9q21.3 (UBQLN1), 13q14.2 (miR-15a/16 and TRIM13), 13q34 (CUL4A and ING1), and 1p21 299 
(RPL5). Mutation of BCOR, UBR5, SP140, CCND1 and WHSC1 were also significantly over-300 
represented in MCL compared to other subtypes, and were associated with this cluster. These 301 
data show that different subtypes of B-NHL are defined by characteristic sets of co-associated 302 
genetic alterations that affect multiple hallmarks.  303 
 304 
Combinations of clonal genetic alterations define B-NHL subtypes 305 
Our data have revealed statistical enrichment of individual genetic alterations in subtypes of B-306 
NHL, and pairwise relationships between different genetic alterations that define clusters of 307 
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subtype-specific events. However, individual genetic alterations from disease-specific clusters 308 
are also observed at variable frequencies in other B-NHL subtypes (Figure 6A). We therefore 309 
investigated whether the combination of multiple genetic alterations from each cluster, rather 310 
than the presence or absence of a single alteration, were pathognomonic. By enumerating the 311 
number of genetic alterations from each disease-specific cluster in each tumor, we found that 312 
this was indeed the case. Specifically over half of all BL, FL and MCL tumors possessed ≥3 313 
genetic alterations defined by their respective subtype-specific clusters (Figure 6). These rates 314 
were significantly higher than those observed in other diseases (Fisher P <0.001 for all 315 
comparisons). For example, DLBCL and FL share many of the same recurrently mutated genes, 316 
particularly when considering the C3/EZB subtype of DLBCL3,4. Thus, one or more FL cluster 317 
alterations are found in 93% of FL tumors, but also in 54% of DLBCL tumors. However, FL 318 
tumors have a significantly higher rate of accumulation of these mutations, with 68% of FL 319 
tumors bearing ≥3 of the FL cluster alterations but only 18% of DLBCL tumors bearing ≥3 of 320 
these genetic alterations (Fisher P < 0.001). This pattern is also conserved for the BL and MCL 321 
clusters, for which the rate of acquiring ≥3 of the cluster alterations was significantly higher in BL 322 
or MCL compared to other subtypes of B-NHL, respectively. Thus, B-NHL subtypes are defined 323 
by the acquisition of multiple genetic alterations from subtype-associated clusters. 324 
 325 
The co-association of multiple mutations may be suggestive of a clonal structure in which early 326 
driver mutations are clonal and later driver mutations are present in sub-clones. We therefore 327 
utilized ABSOLUTE (Table S16-18) to determine whether co-associated genetic alterations are 328 
present at different clonal fractions, and could therefore be phased to create clonal hierarchies. 329 
This analysis failed for a small subset of cases and could not be performed for X-linked genes 330 
or translocations. However, it clearly revealed the majority of co-associated genetic alterations 331 
were present at cancer cell fractions (CCF) >0.9, which is indicative that each mutation is 332 
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clonally represented in every cancer cell at the time of sampling. These data suggest that 333 
combinations of mutations may therefore be required for effective expansion of lymphoma cells, 334 
such that common precursor cells (CPCs) are not detectable within the clonal structure of the 335 
clinically-detected tumor. These data therefore support the premise of epistatic interactions 336 
between co-occurring genetic alterations in B-NHL.  337 
 338 
DISCUSSION 339 
By performing cross-sectional genomic profiling of a large cohort of tumors, we have defined 340 
genes and functional hallmarks that are recurrently targeted by genetic alterations and showed 341 
that combinations of genetic alterations are disease-defining features of B-NHL subtypes. Some 342 
of the functional hallmarks that we identified have been previously appreciated in other 343 
diseases, with a few exceptions. For example, the mutation of genes with roles in chromatin 344 
modification are known to be a hallmark of FL65 and we observed that over 90% of FLs 345 
possessed mutations in one or more of the genes in this category. However, these mutations 346 
were also observed in two thirds of BL and DLBCL tumors and nearly half of MCLs. There are 347 
subtype-specific patterns of chromatin modifying gene alterations, such as those that we 348 
described for H3K36 methylation in MCL and the unique patterns of SWI/SNF mutations across 349 
GCB-derived B-NHLs. But we suggest that the genetic deregulation of chromatin modification 350 
should be considered a general hallmark of B-NHL. In addition, we suggest that the 351 
deregulation of BCL6 function and perturbation of the ubiquitin proteasome system are 352 
hallmarks of B-NHL that require further investigation. We have highlighted some of the known 353 
substrates of recurrently altered UPS genes from the literature, which shows the potential for 354 
these genetic alterations to contribute to aberrant B-cell receptor signaling and proliferation. 355 
However, many of the genes within these categories have not been functionally studied in the 356 
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context of B-cell lymphoma, which represents a significant gap in our understanding of disease 357 
etiology.  358 
 359 
The role of epistatic interactions between co-occurring genetic alterations is also an emerging 360 
field that requires further investigation. These interactions are not uncommon in cancer66, but 361 
our data show that they are pervasive and disease-defining features of the B-NHL genetic 362 
landscape. Epistasis between co-associated genetic alterations identified in this study requires 363 
formal validation in cell line and/or animal models. However, there are many instances in which 364 
co-occurring genetic alterations that we observed have already been shown to cooperate in 365 
lymphomagenesis. In addition to the aforementioned example of MYD88 and CD79B mutations, 366 
transgenic mouse models of Ezh2 activating mutations or conditional deletion of Crebbp or 367 
Kmt2d have shown that these events are not alone sufficient for lymphomagenesis42,67-71. We 368 
and others have observed a co-association between the mutation of these genes and BCL2 369 
translocations16,21, and the addition of a Bcl2 transgene to these murine models indeed 370 
promoted lymphoma at a significantly higher rate than that observed with the Bcl2 transgene 371 
alone42,67-71. These genetic alterations are therefore significantly more lymphomagenic in 372 
combination than they are alone, which provides proof of principal that an epistatic relationship 373 
exists between these co-occurring genetic alterations. Future studies focusing on other co-374 
occurring mutations, such as MYC translocation and SMARCA4 mutation in BL, CREBBP and 375 
KMT2D mutation in FL, TCF4 copy gain and MYD88 mutation in DLBCL, and ATM mutation and 376 
RPL5 deletion in MCL, should therefore be performed to further explore these concepts and 377 
define their underlying functional relationship. We suggest that combinations of genetic 378 
alterations are likely to more accurately recapitulate the biology of B-NHL than single gene 379 
models, and may reveal contextually different functional roles of genetic alterations depending 380 
on the co-occurring events.  381 
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 382 
In conclusion, we have provided a framework of functional hallmarks and co-occurring genetic 383 
alterations that are enriched within B-NHL subtypes. These genetic alterations likely represent 384 
epistatic interactions that underpin the biology of these tumors, and represent an opportunity for 385 
better understanding lymphoma etiology so that we can identify novel rational approaches for 386 
therapeutic targeting of the underlying biology. 387 
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 604 
FIGURE LEGENDS 605 
Figure 1: Recurrently mutated genes in B-NHL subtypes. An oncoplot shows significantly 606 
mutated genes across our cohort of 755 B-NHL tumors, arranged according to functional 607 
category and frequency. The mutational burden and distribution of mutation types for each case 608 
are shown at the top. Amino acid residues for mutational hotspots and/or domains targeted by 609 
clustered mutations are shown on the right.  610 
 611 
Figure 2: Structural alterations in B-NHL subtypes. A) A circos plot shows translocations of 612 
the MYC (purple), BCL2 (orange) and BCL6 (green) genes, and GISTIC tracks of DNA copy 613 
number gains (red) and losses (blue). B-C) Volcano plots of integrative analysis results showing 614 
the changes in gene expression of genes within peaks of DNA copy number gain (B) or loss (C). 615 
The shaded region in B marks genes with significantly increased expression in tumors with 616 
increased copy number compared to those without; the converse is true for the shaded region in 617 
C. D) An oncoplot with DNA copy number losses and gains ranked according to their frequency 618 
shows the distribution of structural alterations across tumors. E) Oncoplots show the overlap of 619 
structural alterations and mutations that target the same genes. P-values are derived from a 620 
Fisher’s exact test (ns, not significant). 621 
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 622 
 623 
 624 
 625 
 626 
Figure 3: Genetic alterations of the ubiquitin proteasome system (UPS) and potential 627 
interplay with BCR signaling. A) A graphical illustration of UPS gene genetic alterations 628 
(mutations, teal; deletions, blue; copy gain, red) and literature supported targets of the UPS 629 
genes. The function of UPS gene targets is categorized according to the hallmarks shown in 630 
figure 1. B) A schematic of the different layers of genetic alterations (mutations, teal; deletions, 631 
blue; copy gain, red) affecting signaling pathways in B-NHL. UPS genes are highlighted with a 632 
yellow halo. 633 
 634 
Figure 4: Subtype-specific clusters of co-occurring genetic alterations. The frequency (bar 635 
graph) and over/under-representation (blue to yellow scale) of mutations and structural 636 
alterations is shown on the left for BL, DLBCL, FL and MCL. Over/under-representation in 637 
molecular Burkitt and cell of origin molecular subtypes is shown for each alteration at the 638 
bottom. The correlation matrix of co-associated (green) and mutually-exclusive (purple) 639 
relationships was clustered and identified groups of co-occurring genetic alterations that were 640 
predominantly over-represented in a single B-NHL subtype. 641 
 642 
 643 
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 644 
 645 
 646 
 647 
 648 
Figure 5: Subtype-specific patterns of SWI/SNF complex mutations. A) An oncoplot shows 649 
the frequency of genetic alterations in genes that encode components of the SWI/SNF complex. 650 
B) A schematic of the SWI/SNF complex shows recurrently mutated genes, ARID1A, 651 
SMARCA4 and BCL7A, and the BCL11A gene that is targeted by 2p15 DNA copy number 652 
gains. C-E) Lollipop plots show the distribution of mutations in the SWI/SNF components 653 
ARID1A (C), SMARCA4 (D), and BCL7A (E). F) A heatplot shows the location of chromosome 654 
2p DNA copy number gains (red) in all tumors (rows) with 2p15 copy gain (n=92, copy number > 655 
2.2) ordered from highest DNA copy number (top) to lowest (bottom). The BCL11A gene is in 656 
the peak focal copy gain. 657 
 658 
Figure 6: Cumulative burden of clonal co-occurring mutations. A) A bar plot shows the 659 
frequency of tumors with genetic alterations from each subtype-defining cluster, grouped by the 660 
number of co-occurring alterations observed per tumor. The frequency of tumors with 3 or more 661 
genetic alterations per tumor is significantly higher in the subtype for which each cluster is 662 
named (***Fisher P-value < 0.001). B-D) An oncoplot, colored by cancer cell fraction (CCF) from 663 
ABSOLUTE, shows the representation and clonality of BL cluster (B), FL cluster (C) and MCL 664 
cluster (D) mutations across the dataset. The rate of co-occurrence of multiple genetic 665 
alterations in a single tumor (columns) is observably higher in the subtypes for which the 666 
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clusters are named, and the co-occurring genetics are most often clonal (CCF > 0.9). BL, Burkitt 667 
Lymphoma. HG, other high-grade lymphoma (DHL/THL, HGBL-NOS). DLBCL, diffuse large B-668 
cell lymphoma. FL, follicular lymphoma. MCL, mantle cell lymphoma. LG, other low-grade 669 
lymphoma (CLL/SLL, MZL). 670 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/674259doi: bioRxiv preprint first posted online Jun. 19, 2019; 
10% 20% 30%
Freq.
KMT2D
CREBBP
ARID1A
EZH2
SMARCA4
HIST1H1E
EP300
BCL7A
TET2
WHSC1
ASH1L
HIST1H1C
HIST1H1B
KMT2A
IGLL5
CARD11
PIM1
GNA13
ID3
MYD88
NOTCH1
NOTCH2
STAT6
FOXO1
GNAI2
SGK1
TCF3
TNFAIP3
ATP6V1B2
CD79B
RFTN1
NFKBIE
DUSP2
ATP6AP1
BCL2
ATM
MYC
TP53
CCND3
CCND1
MEF2B
IRF8
TBL1XR1
SPEN
PRDM1
BCL6
BCOR
IRF4
CDC27
UBR5
KLHL6
DTX1
BIRC6
BIRC3
TNFRSF14
B2M
CIITA
CD58
DDX3X
BTG1
BTG2
EEF1A1
SP140
TMEM51
BL DLBCL FL MCL MZL
CLL/SLL
DHL
HGBL-NOS
SOCS1
Multiple
Nonsense/Frameshift
Missense
Mutation Type:
Ch
ro
m
at
in
 
Mo
di
fic
at
io
n
Si
gn
ali
ng
  P
at
hw
ay
s
Ap
op
. / 
Ce
ll C
yc
.
BC
L6
Fu
nc
tio
n
UP
S
Im
m
.
Ot
he
r
10
20
30
0.25
0.50
0.75
1.00
Mutational
Burden
(mutations / Mb)
Nucleotide
Change
C:G > A:T
C:G > T:A
C:G > G:C
T:A > A:T
T:A > C:G
T:A > G:C
InDel
Nucleotide Change:
Residue / Domain
KAT
DNA_binding
HLH
HLH
Cyclin_N
BCL_N
Raftlin
WWE
Protein_Kinase
SET
SET (Y646N/F/S)
Gα
Rhodanese
IRF
Linker_Histone
Linker_Histone
BTB
BTG
BTG
KAT
Helicase
DNA_binding
TMEM51 (E169*)
TIR (L265P)
TPR_11 (Y641N)
(R400Q/G)
ITAM (Y197S/H/N)
Figure 1
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/674259doi: bioRxiv preprint first posted online Jun. 19, 2019; 
MYC
BCL6
BCL2
6q24.2
6q14.1
1p21.3
13q14.2
13q34
9p21.3
11q22.3
9q21.32
1p36.32
10q23.31
2q22.3
10p13
14q31.3
5q23.2
15q15.1
15q11.2
11q22.1
8p23.3
1q43
1q23.3
8q24.23
7q32.2
1p36.11
8q23.3
12q13.13
18q21.31
12q15
1q23.1
1q42.3
1q31.3
7p22.3
7q21.1
18q23
7q36.3
17q23.1
2p15
11q23.3
9p13.3
13q31.3
8p23.3
11q13.4
10q26.3
4p16.3
BL DLBCL FL MCL MZL
CLL/SLL
DHL
HGBL-NOS
TNFAIP3
EEF1A1, IBTK
RPL5
miR-15a*, miR-16*, TRIM13
ING1, CUL4A
CDKN2A, CDKN2B, MTAP
ATM, POU2AF1, DDX10
UBQLN1, FGD3
TNFRSF14, DFFB
PTEN, FAS
ZEB2
RBM17
B2M, TP53BP1
UBE3A
BIRC3*
FBXO25
CEP170
ING3
RCC1
ATF7
TCF4
MDM2*
MEF2D, SETDB1
ARID4B
UCHL5
CDK6
BCL2
WDR60
miR-21
REL, BCL11A, XPO1
KMT2A, CXCR5
RNF38, UBAP1
miR-17
PPP2R2D
Gene(s)
C
op
y 
Lo
ss
C
op
y 
G
ai
n
t(-
;-)
ATM
POU2AF1*
-11q22.3
p<0.0001
B2M
TP53BP1*
-15q15.1
p<0.0001 p<0.0001
t(-;18)
BCL2
+18q23
BIRC3
-11q22.1
p<0.0001 TNFAIP3
-6q24.2
ns
TNFRSF14
-1p36.32 p=0.0102
EEF1A1
-6q14.1
ns
Translocations:
IgH partner
IgL partner
non-Ig partner
Copy Number Alterations (CNA):
Bi-allelic loss
Single copy loss Single copy gain
Multiple copy gain
A
D
E
Figure 2
B
0.1
1.0
0.01
0.001
0.0001
0 1 2-1-2
T-test Score
Q
-v
al
ue
0.1
1.0
0.01
0.001
0.0001
0 1 2-1-2
T-test Score
Q
-v
al
ue
Multiple
Nonsense/Frameshift
Missense
Mutation Type:
C
10% 20%
Freq.
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/674259doi: bioRxiv preprint first posted online Jun. 19, 2019; 
PLCG2
BLNK
BTK
SYK
LYN
CD19
αβ
PIP3
ERK
AKT
mTOR
MEK
PI3K
PTEN
UBE3A
ATP6V1B2
ATP6AP1
SOCS1
IBTK
NFκB
Signaling
PKCβCARD11
BCL10
MALT1 BIRC3
TNFAIP3
B
RC3H2KLHL6
IRAK4
IRAK1
TRAF6
NOTCH1/2BCR
DTX1
TLR
DUSP2
MYD88
UBR5
UCHL5
IBTK
TRIM13
CUL4A
FOXB25
UBE3A
CDC27
BIRC3
RC3H2
E2F1
LYN
CCND1
BTK
IKBKG
ELK1
MDM2
AKT
DDB2
BCL10
PAIP2
SOCS1
KLHL6
CCNA1
BIRC6
DTX1
NOTCH1 TNFAIP3
NEMO
RNF38
TP53
UPS
Signaling
Apoptosis & C
ell
 C
yc
le
O
th
e
r
A
Figure 3
TCF4
Ig expressionTCF43
TCF4ID3
TRIM13
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/674259doi: bioRxiv preprint first posted online Jun. 19, 2019; 
SMARCA4
CCND3
ID3
MYC_tx
MYC
DDX3X
GNAI2
GNA13
FOXO1
TCF3
TMEM51
ARID1A
BCL6
CARD11
TET2
BIRC6
CIITA
NFKBIE
PRDM1
CD58
DUSP2
BTG2
EP300
TNFAIP3
TBL1XR1
IRF4
AMP_10q26.3
AMP_18q21.31
AMP_18q23
MYD88
CD79B
BCL6_tx
PIM1
IGLL5
BTG1
DTX1
HIST1H1B
B2M
SOCS1
SGK1
HIST1H1E
RFTN1
KMT2A
MEF2B
KLHL6
HIST1H1C
STAT6
EEF1A1
TNFRSF14
IRF8
BCL7A
KMT2D
BCL2_tx
CREBBP
BCL2
EZH2
ATP6V1B2
ATP6AP1
DEL_10q23.31
AMP_1q23.1
AMP_1q31.3
AMP_12q13.13
AMP_12q15
AMP_7p22.3
AMP_7q21.2
AMP_7q36.3
AMP_1q42.3
AMP_2p15
AMP_8p23.3
TP53
DEL_8q24.23
AMP_11q13.4
AMP_11q23.3
AMP_13q31.3
AMP_9p13.3
AMP_4p16.3
DEL_2q22.3
DEL_1p36.11
DEL_1p36.32
DEL_6q24.2
DEL_6q14.1
DEL_15q11.2
DEL_15q15.1
AMP_8q23.3
AMP_17q23.1
DEL_1q23.3
DEL_1q43
BIRC3
ATM
DEL_11q22.1
DEL_11q22.3
DEL_8p23.3
DEL_1p21.3
DEL_9q21.32
DEL_9p21.3
DEL_13q14.2
DEL_13q34
DEL_10p13
DEL_7q32.2
DEL_14q31.3
DEL_5q23.2
WHSC1
BCOR
UBR5
SP140
CCND1
ASH1L
CDC27
NOTCH1
SPEN
NOTCH2
S
M
A
R
C
A
4
C
C
N
D
3
ID
3
M
Y
C
_t
x
M
Y
C
D
D
X
3X
G
N
A
I2
G
N
A
13
FO
X
O
1
TC
F3
TM
E
M
51
A
R
ID
1A
B
C
L6
C
A
R
D
11
TE
T2
B
IR
C
6
C
IIT
A
N
FK
B
IE
P
R
D
M
1
C
D
58
D
U
S
P
2
B
TG
2
E
P
30
0
TN
FA
IP
3
TB
L1
X
R
1
IR
F4
A
M
P
_1
0q
26
.3
A
M
P
_1
8q
21
.3
1
A
M
P
_1
8q
23
M
Y
D
88
C
D
79
B
B
C
L6
_t
x
P
IM
1
IG
LL
5
B
TG
1
D
TX
1
H
IS
T1
H
1B
B
2M
S
O
C
S
1
S
G
K
1
H
IS
T1
H
1E
R
FT
N
1
K
M
T2
A
M
E
F2
B
K
LH
L6
H
IS
T1
H
1C
S
TA
T6
E
E
F1
A
1
TN
FR
S
F1
4
IR
F8
B
C
L7
A
K
M
T2
D
B
C
L2
_t
x
C
R
E
B
B
P
B
C
L2
E
ZH
2
A
TP
6V
1B
2
A
TP
6A
P
1
D
E
L_
10
q2
3.
31
A
M
P
_1
q2
3.
1
A
M
P
_1
q3
1.
3
A
M
P
_1
2q
13
.1
3
A
M
P
_1
2q
15
A
M
P
_7
p2
2.
3
A
M
P
_7
q2
1.
2
A
M
P
_7
q3
6.
3
A
M
P
_1
q4
2.
3
A
M
P
_2
p1
5
A
M
P
_8
p2
3.
3
TP
53
D
E
L_
8q
24
.2
3
A
M
P
_1
1q
13
.4
A
M
P
_1
1q
23
.3
A
M
P
_1
3q
31
.3
A
M
P
_9
p1
3.
3
A
M
P
_4
p1
6.
3
D
E
L_
2q
22
.3
D
E
L_
1p
36
.1
1
D
E
L_
1p
36
.3
2
D
E
L_
6q
24
.2
D
E
L_
6q
14
.1
D
E
L_
15
q1
1.
2
D
E
L_
15
q1
5.
1
A
M
P
_8
q2
3.
3
A
M
P
_1
7q
23
.1
D
E
L_
1q
23
.3
D
E
L_
1q
43
B
IR
C
3
A
TM
D
E
L_
11
q2
2.
1
D
E
L_
11
q2
2.
3
D
E
L_
8p
23
.3
D
E
L_
1p
21
.3
D
E
L_
9q
21
.3
2
D
E
L_
9p
21
.3
D
E
L_
13
q1
4.
2
D
E
L_
13
q3
4
D
E
L_
10
p1
3
D
E
L_
7q
32
.2
D
E
L_
14
q3
1.
3
D
E
L_
5q
23
.2
W
H
S
C
1
B
C
O
R
U
B
R
5
S
P
14
0
C
C
N
D
1
A
S
H
1L
C
D
C
27
N
O
TC
H
1
S
P
E
N
N
O
TC
H
2
Over-RepresentedUnder-Represented
0.001 0.0011
Q-value
Co-AssociatedMutually Exclusive
0.001 0.0011
Q-Value
20 40 60
Freq.
En
ric
hm
ent
20 40 60
En
ric
hm
ent Freq.
20 40 60
En
ric
hm
ent Freq.
20 40 60
En
ric
hm
ent Freq.
BL DLBCL FL MCL
mBL
COO
0.001 0.0011
Q-value
mBLnon-mBL
ABC-likeGCB-like
BL cluster
DLBCL cluster
FL cluster
MCL cluster
CNA cluster
Figure 4
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/674259doi: bioRxiv preprint first posted online Jun. 19, 2019; 
ARID BAF250_C
0 2285aa400 800 1200 1600 2000
0
8 ARID1A
HSA BRK SNF2_N Helica.. SnAC Brom..
0 1647aa400 800 1200
0
5 SMARCA4
BCL_N
0 210aa100
0
19 BCL7AW31
M1
R11
P158
Q200
T910 R1192
# 
M
ut
at
io
ns
Amino acid position
BCL7A
BCL11A
ARID1A
SMARCA4Multiple Nonsense/Frameshift MissenseAlteration Type:
BL DLBCL FL MCL
ARID1A
SMARCA4
BCL7A
BCL11A
19%
24%
7%
11%
7%
3%
7%
21%
15%
8%
11%
18%
6%
6%
0%
2%
Copy gain
A B
C
D
E
F
p16.1 p14
BCL11A
p24.1p25.2 p22.1 p12
Chromosome 2, p-arm
Figure 5
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/674259doi: bioRxiv preprint first posted online Jun. 19, 2019; 
MYC
ID3
TCF3
CCND3
SMARCA4
ARID1A
GNA13
GNAI2
FOXO1
TMEM51
BL HG DLBCL FL MCL LG
1.0
0
0.5
CCF
BL HG DLBCL FL MCL LG
KMT2D
CREBBP
BCL2
TNFRSF14
EZH2
-10q23.31
IRF8
BCL7A
ATP6V1B2
EEF1A1
STAT6
BL HG DLBCL FL MCL LG
-1p21
ATM
-13q34
-13q14.2
-11q22.3
-11q22.1
-9q21.32
-9p21.3
-1q23.3
-1q43
-10p13
-8p23.3
BIRC3
0%
20%
40%
60%
80%
100%
BL
DL
BC
L FL
MC
L
%
 o
f t
um
or
s
0%
20%
40%
60%
80%
100%
BL
DL
BC
L FL MC
L
0%
20%
40%
60%
80%
100%
BL
DL
BC
L FL
MC
L
BL Cluster Alterations FL Cluster Alterations MCL Cluster Alterations
0 per tumor
1 per tumor
2 per tumor
≥3 per tumor
# of Alterations
B
A
C
D
Figure 6
*** *** *** *** ***
***
*** ***
***
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/674259doi: bioRxiv preprint first posted online Jun. 19, 2019; 
